UNSPSC 51142565: Pramipexole dihydrochloride monohydrate

This classification denotes a dopamine agonist and antiparkinsonian agent with the molecular formula C10H17N3S.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3D867NP06J, chemically known as 2,6-benzothiazolediamine, 4,5,6,7-tetrahydro-n6-propyl-, dihydrochloride, (s)- but more generally known as pramipexole dihydrochloride, which bears US NIH Compound Identifier 119569. European Medicines Agency schedules Pramipexole dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04004MIG.

Most nations, for tariff and trade purposes, schedule pramipexole dihydrochloride monohydrate under HS 29341000. SMILES: CCCN[C@H]1CCC2C(SC(N2)N)C1.O.CL.CL.

UNSPSC 51142565 Pramipexole dihydrochloride monohydrate is a Commodity code that nominally covers a specific pharmaceutical active ingredient used to treat Parkinson's disease and restless leg syndrome. However, the recent state and local procurement activity tagged to this code does not align with the pharmaceutical scope—Seminole County, Florida posted an IFB for naloxone and drug deactivation systems, which are opioid-overdose reversal agents and harm-reduction equipment entirely unrelated to pramipexole. State and local agencies purchasing under this code show little relevant recent activity; the single opportunity on record appears to reflect a tagging error rather than genuine demand for the active ingredient itself.

The Seminole County naloxone procurement (IFB 60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract carried a two-year initial term with a one-year renewal option, fixed-fee pricing, and standard compliance requirements including drug-free workplace certification, E-Verify, workers' compensation, and commercial general liability insurance. The opportunity was potentially FEMA-funded, adding federal regulatory overlay. Because the recent-opportunity record contains no other solicitations under this code and the single posting reflects pharmaceutical misclassification rather than genuine market demand for pramipexole, the code offers minimal signal for business development targeting state and local health, corrections, or procurement departments.